Wakai Ryouji, Ishitsuka Masayuki, Kishimoto Toshihiko, Ochiai Tomoshiro, Nacher Jose C
Department of Information Science, Faculty of Science, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan.
Department of Molecular Biology, Faculty of Science, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan.
PLoS One. 2017 Nov 6;12(11):e0186353. doi: 10.1371/journal.pone.0186353. eCollection 2017.
One of the most aggressive forms of breast cancer is inflammatory breast cancer (IBC), whose lack of tumour mass also makes a prompt diagnosis difficult. Moreover, genomic differences between common breast cancers and IBC have not been completely assessed, thus substantially limiting the identification of biomarkers unique to IBC. Here, we developed a novel statistical analysis of gene expression profiles corresponding to microdissected IBC, non-IBC (nIBC) and normal samples that enabled us to identify a set of genes significantly associated with a specific disease state. Second, by using advanced methods based on controllability network theory, we identified a set of critical control proteins that uniquely and structurally control the entire proteome. By mapping high change variance genes in protein interaction networks, we found that a large statistically significant fraction of genes whose variance changed significantly between normal and IBC and nIBC disease states were among the set of critical control proteins. Moreover, this analysis identified the overlapping genes with the highest statistical significance; these genes may assist in developing future biomarkers and determining drug targets to disrupt the molecular pathways driving carcinogenesis in IBC.
炎性乳腺癌(IBC)是最具侵袭性的乳腺癌形式之一,其缺乏肿瘤肿块也使得难以迅速做出诊断。此外,普通乳腺癌与IBC之间的基因组差异尚未得到全面评估,从而极大地限制了对IBC特有的生物标志物的识别。在此,我们针对显微切割的IBC、非IBC(nIBC)和正常样本的基因表达谱开展了一项新颖的统计分析,这使我们能够识别出一组与特定疾病状态显著相关的基因。其次,通过使用基于可控性网络理论的先进方法,我们识别出一组独特且在结构上控制整个蛋白质组的关键调控蛋白。通过在蛋白质相互作用网络中映射高变化方差基因,我们发现,在正常与IBC及nIBC疾病状态之间方差发生显著变化的基因中,有很大一部分在统计学上具有显著意义,且属于关键调控蛋白集合。此外,该分析确定了具有最高统计学意义的重叠基因;这些基因可能有助于未来生物标志物的开发,并确定破坏驱动IBC致癌作用分子途径的药物靶点。